UTHR
United Therapeutics Corp
United Therapeutics Corp historical holders
total: 1
Pzena Investment Management United Therapeutics Corp transactions over time
- Total transactions:
- 16
- New positions:
- 3
- Sold out:
- 3
- Added:
- 5
- Reduced:
- 5
- Held since:
- 2023 Q1
- Held for:
- 6 quarters
- Latest activity:
- 2024 Q3
Richard Pzena has been an institutional investor in United Therapeutics Corp (UTHR) since 2020 Q2. According to 2026 Q1 report, Richard Pzena doesn't hold any shares. The fund/company first acquired UTHR in 2020 Q2, initially purchasing 5,278 shares. Richard Pzena later completely sold out the position and reinvested in UTHR again in 2023 Q1. Since the initial investment, Pzena Investment Management has made 15 more transactions in this position.
When did Richard Pzena exit their UTHR position?
Richard Pzena no longer holds United Therapeutics Corp (UTHR). They sold off their entire position in 2024 Q3, closing out an investment that began in 2020 Q2.
When did Richard Pzena first invest in UTHR?
Richard Pzena first invested in United Therapeutics Corp (UTHR) in 2020 Q2 at the reported quarter-end price of $121.07 per share, acquiring 5,278 shares in their initial purchase.
What is Richard Pzena's average cost basis for UTHR?
Based on historical transaction data, Richard Pzena's estimated cost basis for United Therapeutics Corp (UTHR) is approximately $223.35 per share. This represents their average reported price* across all buy transactions.
Has Richard Pzena reinvested in UTHR after selling?
Yes, Richard Pzena has shown renewed interest in United Therapeutics Corp (UTHR). After completely selling their position, they reinitiated an investment in 2023 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $223.35
- Weighted AVG sell price:
- $310.08
UTHR transactions history by Pzena Investment Management
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$318.55
|
|
-100% (-1,599)
|
-0%
|
|
2024 Q2
|
0.00%
|
1,599
|
$318.55
|
$509,361
|
-23.75% (-498)
|
-0%
|
|
2024 Q1
|
0.00%
|
2,097
|
$229.72
|
$481,723
|
+3.71% (+75)
|
+0%
|
|
2023 Q4
|
0.00%
|
2,022
|
$219.89
|
$444,618
|
+8.53% (+159)
|
+0%
|
|
2023 Q3
|
0.00%
|
1,863
|
$225.87
|
$420,796
|
-10.17% (-211)
|
-0%
|
|
2023 Q2
|
0.00%
|
2,074
|
$220.75
|
$457,836
|
+21.64% (+369)
|
+0%
|
|
2023 Q1
|
0.00%
|
1,705
|
$223.96
|
$381,852
|
new
|
+0%
|
|
2022 Q2
|
0.00%
|
0
|
$179.55
|
|
-100% (-2,768)
|
-0%
|
|
2022 Q1
|
0.00%
|
2,768
|
$179.55
|
$497,000
|
+7.00% (+181)
|
+0%
|
|
2021 Q4
|
0.00%
|
2,587
|
$216.08
|
$559,000
|
-7.47% (-209)
|
-0%
|
|
2021 Q3
|
0.00%
|
$184.55
|
+21.78% (+500)
|
|||
|
2021 Q2
|
0.00%
|
$179.44
|
new
|
|||
|
2021 Q1
|
0.00%
|
$151.78
|
-100% (-4,289)
|
|||
|
2020 Q4
|
0.00%
|
$151.78
|
-15.79% (-804)
|
|||
|
2020 Q3
|
0.00%
|
$100.92
|
-3.51% (-185)
|
|||
|
2020 Q2
|
0.00%
|
$121.07
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.